Optipranolol Related Published Studies
Well-designed clinical trials related to Optipranolol (Metipranolol Ophthalmic)
[Measuring retinal circulation with the Heidelberg retinal flowmeter: reproducibility of data and no effect of metipranolol in normal probands] [2000.11]
Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. [2000.02]
A comparison of the efficacy of various metipranolol-pilocarpine combinations in patients with ocular hypertension and primary open-angle glaucoma. [1994.06]
Ocular macro- and microcirculation after topical application of clonidine and metipranolol. [1994.05]
Metipranolol-induced adverse reactions: I. The rechallenge study. [1992]
Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers. [1989.01]
[Changes in lung function following administration of eyedrops containing timolol, metipranolol, pindolol and pilocarpine in healthy probands and patients with mild bronchial asthma] [1987.10.01]
[Mid-term results of a double-blind study comparing metipranolol to timolol in the treatment of primary open-angle glaucoma] [1987]
[Metipranolol 0.1%: effect of a single dose on the nycthemeral pressure curve in an eye with chronic primary open-angle glaucoma] [1987]
Well-designed clinical trials possibly related to Optipranolol (Metipranolol Ophthalmic)
Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. [1997.05]
Influence of topical anesthesia on tonometric values of intraocular pressure. [1994]
Assessment of systemic effects of different ophthalmic beta-blockers in healthy volunteers. [1991.06]
[Comparison in healthy volunteers of the systemic beta adrenergic receptor blockade by beta blockader eye drops] [1989]
[Elevation of intraocular pressure following Nd-YAG laser capsulotomy. Pathogenesis and preventive therapy] [1987.10]
Other research related to Optipranolol (Metipranolol Ophthalmic)
Early conjunctival changes following treatment with metipranolol and preservatives are not reversible with dexamethasone. [1997.07]
Metipranolol-associated nongranulomatous anterior uveitis. [1997.06]
Acute pulmonary edema associated with ocular metipranolol use. [1995.04]
Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. [1993.01]
[Are metipranolol eyedrops responsible for intraocular side effects?] [1992.12]
Reduction of cardiovascular side effects associated with ocular administration of metipranolol by inclusion in polymeric nanocapsules. [1992.09]
Influence of the concentration of metipranolol eye drops on the drug concentration in human aqueous humour. [1991]
Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. [1989.02]
Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension. [1988.11]
[Asthma and beta-blocker eye drops (timolol, metipranolol, carteolol). Inhibition of chronotropic effects of isoprenaline] [1988.09]
[Comparison of the effects of carteolol and metipranolol eyedrops on the ventilatory and cardiovascular functions in asthmatics] [1987]
Other possibly related research studies
Medical therapy cost considerations for glaucoma. [2003.07]
Cost analysis of glaucoma medications: a 3-year review. [2002.08]
Daily cost of beta-adrenergic blocker therapy. [1997.07]
Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993-2004. [2006]
Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. [2005.06]
Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. [2004.12]
Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. [2001.11]
Contact dermatitis to topical drugs for glaucoma. [2001.12]
[Contact allergy to eyedrops containing beta-blockers] [1998.05.02]
Effects of beta-blockers association with pilocarpine on rabbit intraocular pressure and heart rate. [1997.04]
Uveitis associated with topical beta-blockers. [1996.10]
Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. [1994.08]
Effect of topical beta blockers on corneal epithelial wound healing in the rabbit. [1994.05]
Topical ophthalmic beta blockers: a comparative review. [1993.01]
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. [1992.05]
[Systemic complications of beta-blocking eyedrops. Apropos of 6 cases] [1989.01]
[Comparative multicenter study of carteolol eyedrops with other beta blockers in 768 patients under normal conditions] [1988.02]
|
